Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 293 for “"Pancreatic Cancer"”.
-
Fibroblast Heterogeneity In Pancreatic Cancer Immunity
… subsets. Although well studied in wound healing, cancer associated fibroblasts (CAFs) are incredibly heterogeneous, leading to contradictions as to the roles CAFs play in the tumor microenvironment (TME). CAFs were thought to be a barrier to treatment of pancreatic ductal adenocarcinoma (PDAC). …
-
A Predictive Model for Pancreatic Cancer Diagnosis
Pancreatic ductal adenocarcinoma (PDAC), a specific type of pancreatic cancer, has a five-year survival rate of 8.5% and is the third-deadliest cancer in the United States. However, earlier detection can raise survival rates dramatically. In this thesis, we investigate the hypothesis that …
-
Hospital and Medical Care Days in Pancreatic Cancer
… between diagnosis and death in patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis …
-
Role and Regulation of Epha2 In Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cancer cause of death in the US. Gemcitabine is the first-line therapy for this disease, but unfortunately it shows only very modest benefit. The focus of the current study was to investigate the role and regulation of EphA2, a receptor …
-
The Role of Tak1 In Pancreatic Cancer Development
<p>Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States and the fifth leading cause of cancer-related mortality worldwide. Pancreatic cancer is a big challenge in large due to the lack of early symptoms. In addition, drug resistance is a major obstacle to …
-
Metabolically rewiring pancreatic stromal cells in pancreatic cancer
Pancreatic cancer (PC) is a lethal malignancy characterised by chemoresistance and metastatic spread. This is largely due to the presence of dense stromal fibrosis which distorts tumour vasculature. This limits nutrient, oxygen and chemotherapy perfusion into pancreatic tumours and promotes …
-
Molecular Mechanisms of Metabolic Reprogramming in Pancreatic Cancer
<p>Pancreatic cancer ranks as third deadliest cancer worldwide in both men and women. The lack of diagnostic methods, chemo-resistance and invasiveness of the disease diminishes the overall survival rate in patients. Dysregulated glucose metabolism and several molecular determinants including …
-
Pancreatic Cancer - Early Detection, Prognostic Factors, and Treatment
Background: Pancreatic cancer is the fourth leading cause of cancer-related death. Only about 6% of patients are alive 5 years after diagnosis. One reason for this low survival rate is that most patients are diagnosed at a late stage, when the tumor has spread to surrounding tissues or distant …
-
Pancreatic Cancer: Oncomicrobes, Electric Fields, and Fluid Flow
The pancreatic tumor microenvironment exhibits remarkable complexity, prompting critical investigations into how the microbiota influences tumor progression and how stromal elements impact interstitial fluid dynamics. This dissertation examines dual aspects of this complexity: first, by elucidating …
-
Oncofetal Proteins Drive Aggressive Disease in Basal Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer arising from the exocrine pancreas. Unlike most other solid tumors, incidence and mortality from PDAC continues to rise in the United States. PDAC is typically diagnosed after it has metastasized to other organs, and the only treatment …
-
Altered Responses to Endoplasmic Reticulum Stress In Pancreatic Cancer
<p> <p> Pancreatic ductal adenocarcinoma (PDAC) represents the fourth most common cause of cancer-associated death in the United States. Little progress has been made in understanding how proteotoxic stress affects rapidly proliferating pancreatic tumor cells. Endoplasmic reticulum (ER) stress …
-
Development of Novel Therapeutic Strategies for Pancreatic Cancer Treatment
<p>Pancreatic cancer (PanCa) is the third deadliest cancer in the USA due to the late diagnosis and development of chemo-resistance, with a 5-year survival rate of less than 10%. The prognosis of patients with pancreatic ductal adenocarcinoma is extremely poor, and current therapies such as …
-
Novel imaging biomarkers and resection strategies in pancreatic cancer
Contains fulltext : 312719.pdf (Publisher’s version ) (Open Access)
-
Artificial intelligence for pancreatic cancer guided by clinical need
Contains fulltext : 326579.pdf (Publisher’s version ) (Open Access)
-
Development of novel polymeric nanoparticles for pancreatic cancer therapy
Pancreatic cancer sufferers are faced with a dire prognosis in part because no curative chemotherapy regimen exists. The first-line pancreatic cancer combination therapy of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) comes with significant toxicity and is only tolerable by …
-
The role of tumor-associated macrophages in pancreatic cancer
… and efficient therapy, it is projected that pancreatic cancer (PaC) will become the second leading cause of cancer-related death in the U.S. by 2030. Conventional therapies provide very limited benefit to human patients. Surgery, as a potential cure, is only available for a small proportion …
-
Metabolic and Lifestyle related risk factors for pancreatic cancer
Background and aims: In spite of the fact that pancreatic cancer is a relatively infrequent disease, it ranks 8th in the worldwide ranking of cancer death due to the poor prognosis. The mortality rate is almost as high as the incidence with a M/I ratio of 98%, indicating an extremely dismal …
-
Novel biomarker identification in pancreatic cancer using Raman spectroscopy
Pancreatic cancer presents an increasing mortality burden, with little improvement in survival rates since 1970, largely because of the non-resectable status of most tumours at diagnosis and high rate of recurrence after resection. Currently, there are significant problems with accurately …
-
Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer
Most pancreatic cancer patients receiving gemcitabine chemotherapy eventually develop resistance to gemcitabine. To improve survival and prognosis of pancreatic cancer patients, better understanding the mechanisms of gemcitabine resistance and discovery of new therapeutic targets are required. In …
-
Validation of AXL as a Therapeutic Target in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDA), a leading cause of cancer-related death in the US, has a high metastatic rate that is associated with persistent immune suppression. AXL, a member of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family, has been identified as a critical factor that …
Page 1 of 15